Publication

Thermoresponsive fluorinated small-molecule drugs: a new concept for efficient localized chemotherapy

Publications associées (31)

Recent Considerations in the Application of RAPTA-C for Cancer Treatment and Perspectives for Its Combination with Immunotherapies

Paul Joseph Dyson, Patrycja Nowak-Sliwinska, Magdalena Rausch

The organometallic ruthenium(II) [Ru(arene)Cl2PTA] PTA - 1,3,5-triaza-7-phosphaadamantane compound, RAPTA-C, represents an innovative anti-cancer therapeutic and a better-tolerated alternative to platinum (Pt)-based chemotherapeutic drugs in the treatment ...

WILEY2019

Anti-angiogenic immunotherapy for lung cancer

Ece Kadioglu

Lung cancer is the leading cause of cancer-associated deaths worldwide. Platinum-based chemotherapy is the most common therapeutic approach in advanced non-small cell lung cancer (NSCLC), particularly for tumors that carry non-druggable activating mutation ...

EPFL2019

Functionalization of second harmonic generation nanoparticles for theranostic applications

Jérémy Vuilleumier

Nowadays, cancer is one of the leading causes of death in developed countries. The actual medical tools to detect cancer at early stage suffer to their low sensitivity. The design of multimodal nanodevices for in vivo imaging offers the perspective of canc ...

EPFL2019

Chemokine profiling in serum from patients with ovarian cancer reveals candidate biomarkers for recurrence and immune infiltration

Gianrocco Lazzari, Agata Mlynska

The management of advanced ovarian cancer is challenging due to the high frequency of recurrence, often associated with the development of resistance to platinum-based chemotherapy. Molecular analyses revealed the complexity of ovarian cancer with particul ...

SPANDIDOS PUBL LTD2019

Screening-based approach to discover effective platinum-based chemotherapies for cancers with poor prognosis

Gerardo Turcatti, Damiano Banfi, Paul Joseph Dyson, Fabien Kuttler, Hristo Plamenov Varbanov

Drug combinations are extensively used to treat cancer and are often selected according to complementary mechanisms. Here, we describe a cell-based high-throughput screening assay for identification of synergistic combinations between broadly applied plati ...

2019

Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance

Olivier Michielin, Filipe Amândio Brandão Sanches Vong Martins

Immune-checkpoint inhibitors (ICIs), including anti-cytotoxic T lymphocyte antigen 4 (CTLA-4), anti-programmed cell death 1 (PD-1) and anti-programmed cell death 1 ligand 1 (PD-L1) antibodies, are arguably the most important development in cancer therapy o ...

NATURE PUBLISHING GROUP2019

Dual-responsive polyphosphazene as a common platform for highly efficient drug self-delivery

For clinical applications, simplicity, high efficiency, and low toxicity are key issues in the design of anti-tumor drugs. In this work, a novel dual-responsive drug self-framed delivery system (DSFDS) with high drug delivery efficiency is proposed based o ...

Royal Society of Chemistry2019

Development of Tissue Kallikrein Inhibitors for the Treatment of Netherton Syndrome

Patrick Andreas Gonschorek

There is currently no approved treatment for Netherton syndrome, which is a severe, genetic skin disease characterized by chronic inflammation and excessive peeling of the skin. Even though the molecular disease mechanism has been assigned to the unopposed ...

EPFL2019

Drug Repurposing Approach Identifies a Synergistic Drug Combination of an Antifungal Agent and an Experimental Organometallic Drug for Melanoma Treatment

Paul Joseph Dyson, Olivier Pierre Zava, Tina Riedel

By screening a drug library comprising FDA approved compounds, we discovered a potent interaction between the antifungal agent haloprogin and the experimental organometallic drug RAPTA-T, to synergistically induce cancer cell killing. The combination of th ...

2018

The mechanism of tumour cell death by metal-based anticancer drugs is not only a matter of DNA interactions

Paul Joseph Dyson, Gianni Sava

Platinum drugs are extensively used in the clinic to treat cancer, often leading to a palliative response rather than a cure. While DNA is considered to be the primary target of platinum drugs, there is no clear relationship between cellular platinum accum ...

2018

RANKL Signaling Sustains Primary Tumor Growth in Genetically Engineered Mouse Models of Lung Adenocarcinoma

Nadine Fournier, Caroline Anne-Lyse Contat, Etienne Meylan, Julien Robert Rémi Faget

INTRODUCTION: NSCLC is the leading cause of cancer mortality. Recent retrospective clinical analyses suggest that blocking the receptor activator of NF-κB (RANK) signaling pathway inhibits the growth of NSCLC and might represent a new treatment strategy. M ...

2018